This Phase 2 study aims to evaluate the efficacy, safety, and tolerability of VIR-2482 monoclonal antibody compared to a placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for serious complications from influenza infection.

3000 participants will be enrolled.